The International Journal of Neuropsychopharmacology
September 1, 2026
N Hartman, D Ivkic, M C Dorczok et al.
Neuropsychiatric manifestations of Long COVID (LC) frequently include post-exertional malaise (Cheng et al. , 2025), fatigue, cognitive dysfunction and impairment, sleep disturbances, post-traumatic stress, autonomic dysregulation, pain, inner tension, psychomotor retardation, aberrations in appetite and weight (Badenoch et al. , 2022; O'Mahoney et al. , 2025), showing substantial clinical and...
Frontiers in Psychiatry
2026
C M Diendorfer, C Bum, Ana Weidenauer et al.
Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...
European Neuropsychopharmacology
August 2018
Lucie Bartova, Konstantinos Papageorgiou, Ivan Milenkovic et al.
Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression. Although meaningful antidepressant efficacy of ketamine has also been shown in depressed patients with a history of psychotic symptoms, its administration in psychotic disorders has largely been neglected due to its potential to exacerbate dissociative or psychotic...
European Psychiatry
April 1, 2017
Lucie Bartova, Ana Weidenauer, Markus Dold et al.
IntroductionTreatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant...